--- title: "在 Biogen Inc.(BIIB) 上亏损了吗？加入集体诉讼寻求赔偿——请联系 The Gross Law Firm" description: "在 Biogen Inc.（BIIB）上亏损了吗？加入寻求赔偿的集体诉讼 - 联系 The Gross Law Firm。The Gross Law Firm 正在向在集体诉讼期间购买了 BIIB 股票的股东提供加入寻求赔偿的机会。该诉讼声称，Biogen 在透明度、合规控制和产品组合方面发表了虚假和误导性的声明。鼓励股东在 2024 年 7 月 22 日之前注册参加集体诉讼" type: "news" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/209510225.md" published_at: "2024-07-22T15:55:59.000Z" --- # 在 Biogen Inc.(BIIB) 上亏损了吗？加入集体诉讼寻求赔偿——请联系 The Gross Law Firm > 在 Biogen Inc.（BIIB）上亏损了吗？加入寻求赔偿的集体诉讼 - 联系 The Gross Law Firm。The Gross Law Firm 正在向在集体诉讼期间购买了 BIIB 股票的股东提供加入寻求赔偿的机会。该诉讼声称，Biogen 在透明度、合规控制和产品组合方面发表了虚假和误导性的声明。鼓励股东在 2024 年 7 月 22 日之前注册参加集体诉讼 NEW YORK, July 22, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of **Biogen Inc. (NASDAQ: BIIB).** Shareholders who purchased shares of BIIB during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/biogen-loss-submission-form/?id=91392&from=3 **CLASS PERIOD:** February 3, 2022 to February 13, 2024 **ALLEGATIONS:** The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) Biogen had overstated its efforts to enhance its transparency, corporate governance, and compliance controls and procedures, as well as the efficacy of those controls and procedures; (ii) accordingly, Biogen maintained inadequate compliance controls and procedures in connection with its business operations in foreign countries; (iii) Biogen and/or its employees were engaged in unlawful or otherwise improper conduct in several foreign countries; (iv) the foregoing subjected the Company to a heightened risk of governmental and/or regulatory scrutiny and enforcement action, as well as significant legal, financial, and reputational harm; (v) Biogen overstated the strength of its Alzheimer’s disease related product portfolio, including the its joint efforts and success with pharmaceutical company, Eisai, in launching and providing access to Leqembi; (vi) Biogen also downplayed the negative impact that the Reata Acquisition would have on its FY 2023 non-GAAP diluted EPS; (vii) all the foregoing were likely to have a significant negative impact on Biogen’s 2023 results; and (viii) as a result, the Company’s public statements were materially false and misleading at all relevant times. **DEADLINE: July 22, 2024** Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/biogen-loss-submission-form/?id=91392&from=3 **NEXT STEPS FOR SHAREHOLDERS:** Once you register as a shareholder who purchased shares of BIIB during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is July 22, 2024. There is no cost or obligation to you to participate in this case. **WHY GROSS LAW FIRM?** The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes. **CONTACT:** The Gross Law Firm 15 West 38th Street, 12th floor New York, NY, 10018 Email: dg@securitiesclasslaw.com Phone: (646) 453-8903 ### Related Stocks - [BIIB.US - Biogen](https://longbridge.com/zh-CN/quote/BIIB.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Michael J. Fox 基金會在東部時間 10:12 發佈了新的護理夥伴指南，以支持患有帕金森病的家庭 | 邁克爾·J·福克斯基金會發布了一本名為《共同面對帕金森病》的新數字指南，旨在支持帕金森病患者的照護夥伴。該資源為各個階段的照護夥伴提供實用指導、情感支持和社區見解。指南解決了照護夥伴面臨的挑戰，提供自我照護和醫療護理的工具。該指南是在帕金森 | [Link](https://longbridge.com/zh-CN/news/276457960.md) | | 百勝餐飲旗下的肯德基退出了在英國的 “更好雞肉承諾” | 百勝餐飲的肯德基退出英國的 “更好的雞肉承諾” | [Link](https://longbridge.com/zh-CN/news/276436798.md) | | 諾和諾德公司董事會提議再次選舉 Lars Rebien Sorensen 擔任主席 | 諾和諾德公司董事會提議重新選舉拉斯·瑞比恩·索倫森為董事長 | [Link](https://longbridge.com/zh-CN/news/276440991.md) | | ICICI Prudential 資產管理有限公司增持了百時美施貴寶公司（Bristol Myers Squibb）的股票 $BMY | ICICI Prudential Asset Management Co Ltd 在第三季度將其在百時美施貴寶（NYSE:BMY）的股份增加了 85.8%，目前持有 181,849 股，價值 820 萬美元。其他機構投資者也調整了他們的持股 | [Link](https://longbridge.com/zh-CN/news/276444619.md) | | 分析師對百時美施貴寶股票的評價 | 16 位分析師對百時美施貴寶（NYSE:BMY）進行了評估，結果顯示情緒不一，其中 4 位持看漲態度，3 位稍微看漲，8 位持中立態度，3 位稍微看跌，10 位持看跌評級。12 個月的平均目標價為 60.00 美元，較之前的 51.93 美 | [Link](https://longbridge.com/zh-CN/news/276477307.md) | --- > **免责声明**：本文内容仅供参考，不构成任何投资建议。